Recent Advances in Management of Hidradenitis Suppurativa and Related Comorbidities
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 5095
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory disease that affects approximately 1% of the general population. HS is an underdiagnosed and undertreated condition that severely impairs the quality of life of patients. There is growing evidence that HS is not only a skin disease but also a multisystem inflammatory disease. As a disease of systemic inflammation, HS is associated with numerous comorbidities, including other immune-mediated diseases, metabolic disorders, cardiovascular risk factors, and psychological/psychiatric disorders.
The treatment of HS remains a challenge, although recent advances in understanding the pathogenesis of the disease are allowing the investigation of promising new therapies. In any case, approaches to patients with HS must be comprehensive and multidisciplinary, requiring an early diagnosis of the associated comorbidities as well as the implementation of the preventive and therapeutic measures necessary to avoid future complications. In this sense, it is a topic of great interest to know the potential effect that biological drugs could have in the prevention and control of cardiometabolic comorbidities associated with the systemic inflammation in HS.
This Special Issue invites articles concerning recent advances in the management of HS and related comorbidities and hopes to provide more information that will be useful in future research, as well as in daily practice
Dr. Marcos Antonio González-López
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hidradenitis suppurativa
- diagnostics
- treatment
- comorbidities
- biological therapy
